MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells

Biochemical and Biophysical Research Communications

Volumn 493, Issue 4, 2017, Pages 1478-1484

  Shao, Lijuan ^a,b   Zhang, Bo ^a,b   Wang, Lingxiong ^a   Wu, Liangliang ^a   Kan, Quancheng ^c   Fan, Kexing ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 9; Myeloid derived suppressor cell; Osteopontin; Tumor immune escape

Indexed keywords

CD11B ANTIGEN; GELATINASE B; ISOPROTEIN; MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN 1; OSTEOPONTIN 2; OSTEOPONTIN 3; OSTEOPONTIN 4; UNCLASSIFIED DRUG; MMP9 PROTEIN, MOUSE; PEPTIDE FRAGMENT; SPP1 PROTEIN, MOUSE;

3LL CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL EXPANSION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SPLEEN; SPLEEN CELL; SUPERNATANT; TUMOR ESCAPE; TUMOR GROWTH; TUMOR VOLUME; WILD TYPE; ANIMAL; C57BL MOUSE; ENZYMOLOGY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID-DERIVED SUPPRESSOR CELLS; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85030710865     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.10.009     Document Type: Article

References (34)

1. Almand, B., Clark, J.I., Nikitina, E., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:1 (2001), 678–689.
2. Diaz-Montero, C.M., Salem, M.L., Nishimura, M.I., et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:1 (2009), 49–59.
3. Mandruzzato, S., Solito, S., Falisi, E., et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:10 (2009), 6562–6568.
4. Umansky, V., Blattner, C., Gebhardt, C., Utikal, J., The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel), 4(4), 2016.
5. Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:8 (2009), 4499–4506.
6. Solito, S., Pinton, L., Mandruzzato, S., Brief: myeloid-derived suppressor cells in cancer. J. Pathol. 242:1 (2017), 7–9.
7. Millrud, C.R., Bergenfelz, C., Leandersson, K., On the origin of myeloid-derived suppressor cells. Oncotarget 8:2 (2017), 3649–3665.
8. Lindau, D., Gielen, P., Kroesen, M., et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138:2 (2013), 105–115.
9. Baniyash, M., Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol. Immunother. 65:7 (2016), 857–867.
10. Rangaswami, H., Bulbule, A., Kundu, G.C., Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:2 (2006), 79–87.
11. Shevde, L.A., Samant, R.S., Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 37 (2014), 131–141.
12. Rittling, S.R., Chambers, A.F., Role of osteopontin in tumour progression. Br. J. Cancer 90:10 (2004), 1877–1881.
13. Jia, R., Liang, Y., Chen, R., et al. Osteopontin facilitates tumor metastasis by regulating epithelial-mesenchymal plasticity. Cell Death Dis., 7(12), 2016, e2564.
14. Clemente, N., Raineri, D., Cappellano, G., et al. Osteopontin bridging innate and AdaptivImmunity in autoimmune diseases. J. Immunol. Res., 2016, 7675437.
15. Shi, L., Wang, X., Role of osteopontin in lung cancer evolution and heterogeneity. Semin. Cell Dev. Biol. 64 (2017), 40–47.
16. Rouanne, M., Adam, J., Goubar, A., et al. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. Bmc Cancer, 2016, 16.
17. Théret, N., Musso, O., Turlin, B., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34:1 (2001), 82–88.
18. Turpeenniemi-Hujanen, T., Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:3–4 (2005), 287–297.
19. Zhang, B., Dai, J., Wang, H., et al. Anti-osteopontin monoclonal antibody prevents ovariectomy-induced osteoporosis in mice by promotion of osteoclast apoptosis. Biochem. Biophys. Res. Commun. 452:3 (2014), 795–800.
20. Fan, K., Dai, J., Wang, H., et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheumatism 58:7 (2008), 2041–2052.
21. Tong, X., Li, L., Li, X., et al. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/beta-catenin pathway. Oncotarget 5:21 (2014), 10571–10583.
22. Takafuji, V., Forgues, M., Unsworth, E., et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:44 (2007), 6361–6371.
23. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:4 (2012), 253–268.
24. Kumar, V., Patel, S., Tcyganov, E., et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37:3 (2016), 208–220.
25. Parker, K.H., Beury, D.W., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128 (2015), 95–139.
26. Umansky, V., Sevko, A., Gebhardt, C., Utikal, J., Myeloid-derived suppressor cells in malignant melanoma. J. Dtsch. Dermatol Ges. 12:11 (2014), 1021–1027.
27. Tilli, T.M., Franco, V.F., Robbs, B.K., et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol. Cancer Res. 9:3 (2011), 280–293.
28. Tan, T.K., Zheng, G., Hsu, T.T., et al. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Lab. Invest. 93:4 (2013), 434–449.
29. Ostrand-Rosenberg, S., Tolerance and immune suppression in the tumor microenvironment. Cell Immunol. 299 (2016), 23–29.
30. Sangaletti, S., Tripodo, C., Sandri, S., et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74:17 (2014), 4706–4719.
31. Pio, R., Corrales, L., Lambris, J.D., The role of complement in tumor growth. Adv. Exp. Med. Biol. 772 (2014), 229–262.
32. Venning, F.A., Wullkopf, L., Erler, J.T., Targeting ECM disrupts cancer progression. Front. Oncol., 5, 2015, 224.
33. Pietruszewska, W., Bojanowska-Pozniak, K., Kobos, J., Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study. Otolaryngol. Pol. 70:3 (2016), 32–43.
34. van Kempen, L.C., Coussens, L.M., MMP-9 potentiates pulmonary metastasis formation. Cancer Cell 2:4 (2002), 251–252.